ArticleMolecules (Basel, Switzerland)2019

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.

Sonia Burgaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.